Axsome Therapeutics, Inc. announced on May 27, 2025, that they have settled patent litigation with Hetero Labs regarding the generic version of their product, SUNOSI, allowing Hetero to sell it starting in March 2040, subject to FDA approval. The settlement is still awaiting review by antitrust authorities.